Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Journal of Diabetes Investigation, 12 (4), 651657
This work was supported by grants from the Chung Shan Medical University Hospital (CSH-2022-A-004)
Kelly Tenbrink MD (NPI: 1346482684) lead the clinical team, with additional support from Dr
What should I track besides the scale to reset my goals
Research has examined its role in: GHS-R1a receptor binding, phospholipase C/calcium signalling, and GH vesicle exocytosis studies high-potency reference agonist GH and IGF-1 axis stimulation enhanced potency relative to GHRP-6 and Ipamorelin ACTH and cortisol co-stimulation hypothalamic-pituitary-adrenal axis interaction with the ghrelin receptor Pituitary somatotroph biology GH secretory capacity, somatostatin antagonism, and GHRH co-dependency pharmacology CD36 scavenger receptor binding, PI-3K/AKT1 prosurvival pathway activation, and HIF-1 induction Cardiac protection ischaemia/reperfusion injury, dilated cardiomyopathy, and doxorubicin-induced cardiotoxicity models Anti-fibrotic pathway research PPAR upregulation, TGF-1 and CTGF transcriptional suppression Cytoprotective biology across cardiac, neuronal, and hepatic cell models Idiopathic short stature and GH deficiency reference peptide for GH stimulation test research models GHRP class comparative pharmacology reference compound for SAR studies against GHRP-6, Ipamorelin, and Hexarelin GHRP-2 and Cardioprotection Research GHRP-2 has demonstrated cardioprotective activity in pre-clinical models through its dual GHS-R1a and CD36 receptor pharmacology
US$ 24.69
US$ 22.46
US$ 25.57
